Founded in 2014 with operations in South San Francisco and Paris, DNA Script develops Enzymatic DNA Synthesis (EDS) as an alternative to traditional chemical DNA synthesis. The company’s first commercial product is the SYNTAX Platform/System, a benchtop enzymatic synthesis instrument that enables labs to print synthetic nucleic acids on demand. SYNTAX is positioned to let researchers iterate more rapidly by removing multi‑day waits for third‑party oligo providers. DNA Script says the platform targets genomics and molecular biology applications and aims to increase access to oligo manufacturing. The company frames SYNTAX as a step toward a new paradigm for DNA and RNA synthesis and to transform life‑sciences research. Financially, DNA Script completed a second tranche of its Series C, raising $200 million and bringing total capital raised to $315 million since founding. DNA Script is pioneering enzymatic DNA synthesis (EDS) and is commercializing the SYNTAX benchtop DNA printer to put DNA writing capabilities directly in research and clinical labs. The SYNTAX system is intended to make writing DNA as simple and straightforward as reading DNA, enabling same‑day synthesis of oligonucleotides for faster experiment iteration and diagnostic development. The company plans testing with a select group of partners, a beta program later this year, and to accept orders for the printer next year. Recent funding will accelerate development of its suite of EDS technologies, support the commercial launch of SYNTAX, and help ramp commercial and manufacturing capabilities. DNA Script is also participating in the Molecular Encoding Consortium with the Broad Institute and Harvard University to develop deployable DNA data storage and retrieval technology, a project funded by a $23 million IARPA grant. The company was founded in 2014 in Paris. DNA Script develops enzymatic DNA and RNA synthesis technology to produce rapid, affordable, high-quality synthetic nucleic acids. The company has demonstrated the ability to synthesize 200 nucleotides of DNA with high accuracy, showcased at an academic conference. Its platform combines novel biochemical processes and nucleotide chemistry intended to enable genome-scale synthesis and same-day results. DNA Script positions its technology for applications across drug discovery, diagnostics, agriculture, industrial and food technologies, and DNA data storage. The company was founded in 2014 in Paris. The Series B financing announced in this article provides additional capital to further develop its enzymatic platform and expand applications. DNA Script develops a novel enzymatic process for de novo DNA and RNA synthesis that mimics natural biochemical mechanisms. The company’s platform aims to produce long DNA constructs with higher quality, faster turnaround and reduced use of harsh chemicals compared with traditional chemical synthesis. DNA Script positions this technology to address unmet manufacturing needs in cell and gene therapy and to accelerate genomics research. The company cites potential applications across therapeutics, sustainable chemical production, improved crops and DNA data storage. DNA Script was founded in 2014 in Paris and has been described as aiming to become a global leader in biomanufacturing for cell and gene therapy. Financially, the company has raised $27M to date and was recently awarded $2.7M in non-dilutive financing from Bpifrance. DNA Script develops enzymatic DNA and RNA synthesis technology that mimics natural processes to produce de novo synthetic nucleic acids. Its biochemical approach aims to deliver faster turnaround, higher quality, and greater manufacturing flexibility than traditional chemical synthesis while minimizing the use of harsh chemicals. The company positions itself to accelerate innovation across life sciences, with applications in therapeutics, sustainable chemical production, improved crops, and DNA data storage. Management says recent breakthroughs on the platform have advanced development and the company aims to become a global leader in synthetic DNA manufacturing. The synthetic nucleic acids market exceeds $1 billion annually and DNA Script is focused on scaling to meet demand. Financially, the company has raised $24M to date, including a $13M Series A in September 2017 led by Illumina Ventures.

Total raised

$310M

Funding rounds

6

Latest round

Series C

Latest activity

Jan 2022